Semaglutide: A Breakthrough in Treating AUD with Obesity

Created using ChatSlide

The once-weekly semaglutide trial investigates the potential of GLP-1 agonists in addressing the high mortality rates associated with Alcohol Use Disorder (AUD), alongside obesity management. Conducted as a 26-week, double-blind study with 108 participants who have an AUDIT score over 15, the trial compares semaglutide to a placebo with an additional cognitive behavioral therapy framework. Primary outcomes observed a 41.1% reduction in heavy drinking days, with secondary outcomes highlighting...